Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 195

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 195
---
4
and 2023, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

| ​                                                
 ​                                                | ​                
 ​                
 ($ in thousands) | ​                               
 For the year ended December 31, |    ​ 
 2024 | ​ | ​ |     ​ 
  2023 |
|:-------------------------------------------------|:-----------------|:--------------------------------|-----:|:--|:--|------:|
| City of Hope National Medical Center             | ​                | ​                               |    ​ | ​ | ​ |     ​ |
| CD123                                            | ​                | $                               |    - | ​ | $ |    23 |
| IL13Rα2                                          | ​                | ​                               |  427 | ​ | ​ | 1,115 |
| CS1(1)                                           | ​                | ​                               |    - | ​ | ​ |   188 |
| PSCA(1)                                          | ​                | ​                               |    - | ​ | ​ |    44 |
| Fred Hutchinson Cancer Center - CD20             | ​                | ​                               |  312 | ​ | ​ | 1,254 |
| St. Jude Children's Research Hospital - XSCID(2) | ​                | ​                               | -434 | ​ | ​ |   637 |
| Leiden University Medical Center - RAG1 SCID     | ​                | ​                               |  213 | ​ | ​ |   350 |
| Mayo Clinic(3)                                   | ​                | ​                               | -275 | ​ | ​ |   551 |
| Total                                            | ​                | $                               |  243 | ​ | $ | 4,162 |

| (1) | Licenses and associated sponsored research agreements were terminated in May 2023. |

| (2) | License and associated Data Transfer Agreement were terminated in April 2024. |

| (3) | License and associated sponsored research agreement were terminated in June 2024. |

Ongoing Clinical Trial and Sponsored Research Agreements

IL13Rα2 (MB-101) Clinical Research Support Agreements with City of Hope

Since February 2017, the Company has been party
to a clinical research support agreement for the IL13Rα2-directed CAR T program (the “IL13Rα2 CRA”) with COH, whereby,
the Company has agreed to contribute $0.1 million related to patient costs